-
KeyBanc: Iqvia Holdings' Valuation Might Be Overheated
Monday, November 13, 2017 - 9:41am | 398Read More...Iqvia Holdings Inc (NYSE: Q), formerly known as Quintiles, merged with IMS Health last year to combine its data assets and tools to better compete in the post-Cures Act environment. The Analyst KeyBanc Capital Markets' Donald Hooker downgraded Iqvia's stock rating from Overweight to...
-
The 5 Top-Selling Drugs In The World
Tuesday, September 20, 2016 - 12:09pm | 488Read More...The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...
-
Quintiles Poised To Benefit From Pharmaceutical R&D Outsourcing
Thursday, August 18, 2016 - 11:48am | 310Read More...Argus maintains its Buy rating on Quintiles Transnational Holdings Inc (NYSE: Q) shares. The brokerage also lifted its price target from $75 to $85. The move comes after the company delivered better-than-estimated second-quarter results and an increased outlook on July 27. Analysts Jacob Kilstein...
-
Shares Of Mylan Slightly Higher Following Launch Of Generic Drug
Tuesday, December 29, 2015 - 9:56am | 130Read More...Shares of Mylan NV (NASDAQ: MYL) were trading higher by 0.85 percent early Tuesday morning after the company announced the launch of Linezolid Tablets, 600 mg. Linezolid is a generic version of Pfizer Inc. (NYSE: PFE)'s Zyvox Tablets and is intended for adults and children for the treatment...
-
This Data Offers Insight Into Gilead Sales
Wednesday, April 8, 2015 - 12:44pm | 587Read More...Gilead Sciences, Inc. (NASDAQ: GILD) received new data from IMS Health about the breakdown of its drug prescriptions. Gilead is most known for its hepatitis C medications, Harvoni and Sovaldi. IMS prescription data breaks down how many people are receiving which drug prescriptions in more than...
-
Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform
Friday, April 4, 2014 - 4:44pm | 2444Read More...U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...
-
Helmerich & Payne (HP) To Be Added To S&P 500 Index
Monday, February 22, 2010 - 7:25pm | 74Read More...Standard & Poor's announced on Monday that Helmerich & Payne, Inc. (NYSE: HP) would replace IMS Health, Inc. (NYSE: RX) in the S&P 500 index. Standard & Poor's is making the move because IMS Health is being purchased by affiliates of TPG Capital LP and the Canada Pension Plan...
